Mr. Speaker, I have a petition to present today from a number of Londoners who are very concerned about the trans-Pacific partnership.
The petitioners believe this agreement would threaten to reduce access to medicines by restricting the production and sale of generic medicines. They also believe it would reduce the ability of competitors to enter the marketplace, thereby making medical production monopolies. The biologics portion of the agreement states that pharmaceutical products containing biological ingredients will have market protection for a period of at least eight years, thereby making them very expensive and inaccessible.